CCL3 and myeloid sarcoma: Notably, in patients with RR-MS treated with IFN-β, MIP1α/CCL3 CSF undetectability predicted the absence of clinical/radiological relapses and disability progression 1 year after diagnosis (Stampanoni Bassi et al., 2020).